Close
4

Fermion Oy Fermion Oy

X

Company profile for Kuria Therapeutics

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
Kuria Therapeutics is developing a novel topical Nrf2 activator for important diseases of the eye. Our lead program (KTX-1161) targets the corneal endothelium, where there is strong biologic evidence that activation of Nrf2 can treat and prevent diseases with high unmet medical need. KTX-1161 is currently in preclinical development for the treatment of Fuchs' dystrophy and prevention of corneal endothelial damage associated wi...
Kuria Therapeutics is developing a novel topical Nrf2 activator for important diseases of the eye. Our lead program (KTX-1161) targets the corneal endothelium, where there is strong biologic evidence that activation of Nrf2 can treat and prevent diseases with high unmet medical need. KTX-1161 is currently in preclinical development for the treatment of Fuchs' dystrophy and prevention of corneal endothelial damage associated with cataract surgery.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
Kuria Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
6834 Cantrell Rd, Suite 1651 Little Rock, AR 72207
Telephone
Telephone

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY